Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma

BACKGROUND: The endothelin system is involved in tumour growth. Atrasentan, a selective endothelin-A-receptor antagonist, blocks endothelin signalling. This phase I trial studied combining treatment of interferon-alpha (IFN-α) with atrasentan in renal cell carcinoma (RCC). PATIENTS AND METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Groenewegen, G, Walraven, M, Vermaat, J, de Gast, B, Witteveen, E, Giles, R, Haanen, J, Voest, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261664/
https://www.ncbi.nlm.nih.gov/pubmed/22215065
http://dx.doi.org/10.1038/bjc.2011.515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261664/
https://www.ncbi.nlm.nih.gov/pubmed/22215065
http://dx.doi.org/10.1038/bjc.2011.515

Ejemplares similares